Pembrolizumab with or without chemotherapy for stage IV lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed stage IV non-small cell lung cancer (lung cancer that has spread).
- Your lung cancer type is squamous or non-squamous (both are allowed).
- Your scans show measurable disease (a tumor area that doctors can track).
- You do not have active autoimmune disease that needed immune-suppressing medicines in the last 2 years.
- You do not currently have lung inflammation (pneumonitis or interstitial lung disease) or a past case that needed steroids.
- You do not have an infection that requires taking strong (systemic) medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
This trial tests if the immunotherapy drug pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer by boosting the body's own immune cells (T-cells) to fight the cancer. It's for people who have not had any prior cancer treatment.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.